SAN DIEGO, June 5, 2017 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), a leading medical device company focused on
transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced the PRECICE®
system and PRECICE UNYTE™ platform from NuVasive Specialized
Orthopedics (NSO) are featured in the June
2017 supplement of the Journal of Orthopaedic Trauma (JOT),
which demonstrates a lower complication rate, greater patient
comfort and faster healing in comparison to traditional
treatments1.
NSO, a NuVasive division focused on the design and innovation of
disruptive orthopedic solutions, developed a proprietary platform
of magnetically adjustable implant systems that include:
- The PRECICE system is an intramedullary device that once
implanted utilizes an External Remote Controller (ERC) to
non-invasively lengthen the femur and tibia. Through propriety
magnetic technology, the PRECICE ERC lengthens the PRECICE device
with precision rate control. Each patient's lengthening is
customized based on a physician directed program.
- PRECICE UNYTE is an intramedullary solution for
stabilizing and treating difficult to heal fractures and
non-unions. It leverages clinically validated technology based on
the proven principles of compression and distraction osteogenesis
and uses the ERC magnetic technology to apply non-invasive
customized treatment for proper bone healing and restoring natural
bone length.
"Our groundbreaking, non-invasive technology platforms from NSO
have disrupted the spine and orthopedic markets," said Gregory T. Lucier, NuVasive chairman and chief
executive officer. "The positive outcomes from our early clinical
experience with PRECICE UNYTE demonstrate that we are able to treat
complex fractures with our magnetic technology, which will help
transform the lives of patients that previously lacked a formidable
solution."
PRECICE system and PRECICE UNYTE are featured in the June JOT
Supplement, "Intramedullary Limb Lengthening and Compression for
Orthopedic Trauma Surgeons", with five articles authored by
leading surgeons Robert Rozbruch,
M.D., Mitchell Bernstein, M.D.,
Stuart Green, M.D., Austin Fragomen, M.D., and Tracy Watson, M.D.
"I'm honored to report on the success of PRECICE UNYTE
intramedullary compression implant and share the positive results
of our early clinical experience," said Dr. Green, University of California, Irvine, Department of
Orthopaedic Surgery. "The future of this technology is clearly
evident in the JOT supplement, which highlights the key role
engineering research plays in developing medical device innovation.
Patients around the globe will greatly benefit from the new
technology created by the collaboration effort of NSO and the
surgeon community."
PRECICE UNYTE WEBINAR
The Company is hosting a webinar on June
6, 2017 titled, "Treating Challenging Fractures and
Nonunions," featuring Austin
Fragomen, M.D. from the Hospital for Special Surgery,
New York. The webinar will look at
traditional treatment options and highlight new technologies in
intramedullary compression and distraction devices. Click here for
more information and to register.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA)
is a world leader in minimally invasive, procedurally-integrated
spine solutions. From complex spinal deformity to degenerative
spinal conditions, NuVasive is transforming spine surgery and
beyond with innovative technologies designed to deliver
reproducible and clinically proven surgical outcomes. NuVasive's
highly differentiated, procedurally-integrated solutions include
access instruments, implantable hardware and software systems for
surgical planning and reconciliation technology that centers on
achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an
approximate 2,300 person workforce in more than 40 countries around
the world. For more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions you that statements included in this
news release that are not a description of historical facts are
forward-looking statements that involve risks, uncertainties,
assumptions and other factors which, if they do not materialize or
prove correct, could
cause NuVasive's results to differ
materially from historical results or those expressed or implied by
such forward-looking statements. The potential risks and
uncertainties which contribute to the uncertain nature of these
statements include, among others, risks associated with acceptance
of the Company's surgical products and procedures by spine
surgeons, development and acceptance of new products or product
enhancements, clinical and statistical verification of the benefits
achieved via the use of NuVasive's products (including
the iGA™ platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described
in NuVasive's news releases and periodic
filings with the Securities and Exchange
Commission. NuVasive's public filings with
the Securities and Exchange Commission are
available
at www.sec.gov. NuVasive assumes
no obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
1 Fragomen, Austin T. J Orthop
Trauma; Volume 31, Number 6 Supplement, June 2017;
S7-S13
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nuvasive-magnetic-non-invasive-platforms-featured-in-the-journal-of-orthopaedic-trauma-supplement-300468399.html
SOURCE NuVasive, Inc.